Talk

Guest Kim Slocum, President of KDS Consulting, LLC, and former Director, Strategic Planning & Business Development at AstraZeneca, talks about HIT mediated comparative effectiveness research as part of scenario-based strategic planning for the biopharma industry.

A conversation with Jeff Fetterman, President and CEO of ParagonRx, about developing a Risk Evaluation and Mitigation Strategy (REMS) that clinicians will consider useful and that would raise their intent to prescribe.

A conversation with Tom O'Brien, CMO at MotiveQuest LLC, about using social media data mining to spot patterns in conversations early so that pharma marketers can better align their messages with the needs and concerns of consumers and patients.

A conversation with Dr. Frank Antwerpes, President, DocCheck Medical, about the recent survey of the DocCheck physician online community regarding use of social media.

A conversation with Jacqueline Thong, co-founder and CEO of Ubiqi Health, about disease management mobile applications and how pharma marketers can leverage mobile health apps to engage with and learn from patients.

A conversation with Elizabeth A. Cermak, EVP, and Chief Commercial Officerat Pozen, Raj Amin, CEO and Co-Founder of HealthiNation, and Bonin Bough, Senior Global Director of Digital and Social Media, PepsiCo, about the who, what, why behind the Pozen Digital Advisory Board, an esteemed group of digital thought-leaders both in and outside of healthcare.

A conversation with John J. Doyle, Sr. Vice President and Managing Director - Global Market Access at Quintiles, about the need for deeper knowledge of the inherent risks of pharmaceutical products. This need was revealed by The New Health Report 2012, which is based on surveys of biopharmaceutical executives, managed care executives in the U.S., National Health Service executives in the U.K., patients living with chronic disease in both the U.S. and the U.K., and investors who focus on the healthcare sectors.

Guest Saidat Amirkhanova, former Digital Communications Director at sanofi-aventis, discusses the relationship EU pharmaceutical marketers and digital agencies from the perspective of someone with many years of experience on the inside of the industry and who is now working on the outside.

A conversation with Todd D. Clark, President of Value of Insight Consulting (VOI) and the author of pharmahandbook and generichandbook, about the U.S. Rx prescription drug 'Utilization Plateau.' The discussion will feature a recent white paper developed as an excerpt from VOI's new edition of the United States Market: pharmahandbook publication, and focuses on why the pharmaceutical market growth in the United States has slowed dramatically and what the pharmaceutical industry can do to avoid the slow-growth trap.

Pharmaguy interviews Casey Steffen M.Sci., Manager at Biologic Models, about his crowdfunding campaign, which is designed to encourage supporters to share